SpaceX files confidential S-1. $1.75T target makes it the biggest IPO in history.

SpaceX confidentially filed a draft S-1 with the SEC on April 1, targeting a June 2026 NASDAQ listing [CNBC]. The public registration statement is expected the week of May 18–22, satisfying the SEC's 15-day pre-marketing rule [TechStackIPO].

── What shipped ──

The filing targets a $1.75 trillion market value with a $75 billion raise — at scale, the largest IPO in U.S. history by several multiples.

The valuation includes:

• SpaceX core launch business (Falcon 9, Starship, Dragon)
• Starlink (consumer and enterprise satellite internet)
• xAI, absorbed in February (TX_017) — Grok and the X integrations now sit inside SpaceX

At roughly 95x trailing revenue, the figure is rich. PitchBook analysis pegs proper valuation between $1.1T and $1.7T [ARK valuation guide], short of the headline target.

── Why it matters ──

Three structural implications.

One — public market liquidity for AI compute infrastructure. SpaceX's xAI absorption means the IPO carries an implied AI line item. Public-market investors get the first chance to buy a vertically integrated frontier-AI + launch + satellite business as a single security.

Two — secondary market repricing. SpaceX private shares have traded at the $400–500B range until recently. A $1.75T target is a 3–4x repricing in months. This pulls the entire late-stage VC valuation environment higher, particularly for AI-adjacent infra companies.

Three — listing format and lockup. Confidential filing buys flexibility. Direct listing remains possible, but the $75B raise size suggests a traditional IPO. Expect a 90–180 day lockup period that will define secondary supply through early 2027.

── Editor's take ──

The 95x revenue multiple prices in execution that has not yet shipped — Starship cost trajectory, Starlink user growth at scale, xAI's contribution to compute monetisation. The genuine SpaceX bull case is plausible at $1.1–1.5T. Beyond that, you are paying for execution risk on a Musk timetable, which is its own asset class. Buy the long-term thesis on a pullback, not the headline IPO pop.